Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAEGS1646

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	MAR 15	WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS 3	MAR 16	CASREACT coverage extended
NEWS 4	MAR 20	MARPAT now updated daily
NEWS 5	MAR 22	LWPI reloaded
NEWS 6	MAR 30	RDISCLOSURE reloaded with enhancements
NEWS 7	APR 02	JICST-EPLUS removed from database clusters and STN
NEWS 8	APR 30	GENBANK reloaded and enhanced with Genome Project ID field
NEWS 9	APR 30	CHEMCATS enhanced with 1.2 million new records
NEWS 10	APR 30	CA/CAplus enhanced with 1870-1889 U.S. patent records
NEWS 11	APR 30	INPADOC replaced by INPADOCDB on STN
NEWS 12	MAY 01	New CAS web site launched
NEWS 13	MAY 08	CA/CAplus Indian patent publication number format defined
NEWS 14	MAY 14	RDISCLOSURE on STN Easy enhanced with new search and display fields
NEWS 15	MAY 21	BIOSIS reloaded and enhanced with archival data
NEWS 16	MAY 21	TOXCENTER enhanced with BIOSIS reload
NEWS 17	MAY 21	CA/CAplus enhanced with additional kind codes for German patents
NEWS 18	MAY 22	CA/CAplus enhanced with IPC reclassification in Japanese patents
NEWS 19	JUN 27	CA/CAplus enhanced with pre-1967 CAS Registry Numbers
NEWS 20	JUN 29	STN Viewer now available
NEWS 21	JUN 29	STN Express, Version 8.2, now available
NEWS 22	JUL 02	LEMBASE coverage updated
NEWS 23	JUL 02	LMEDLINE coverage updated
NEWS 24	JUL 02	SCISEARCH enhanced with complete author names
NEWS 25	JUL 02	CHEMCATS accession numbers revised
NEWS 26	JUL 02	CA/CAplus enhanced with utility model patents from China
NEWS 27	JUL 16	CAplus enhanced with French and German abstracts
NEWS 28	JUL 18	CA/CAplus patent coverage enhanced
NEWS 29	JUL 26	USPATFULL/USPAT2 enhanced with IPC reclassification
NEWS 30	JUL 30	USGENE now available on STN

NEWS EXPRESS 29 JUNE 2007: CURRENT WINDOWS VERSION IS V8.2,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 05 JULY 2007.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may

result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 19:12:24 ON 31 JUL 2007

=> file .gerry2MBCE
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'MEDLINE' ENTERED AT 19:12:44 ON 31 JUL 2007

FILE 'BIOSIS' ENTERED AT 19:12:44 ON 31 JUL 2007
Copyright (c) 2007 The Thomson Corporation

FILE 'CAPLUS' ENTERED AT 19:12:44 ON 31 JUL 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 19:12:44 ON 31 JUL 2007
Copyright (c) 2007 Elsevier B.V. All rights reserved.

=> S Sorbitol SAME Formulation AND pd<=20031104
   1 FILES SEARCHED...
L1 0 SORBITOL SAME FORMULATION AND PD<=20031104

=> S Sorbitol(S)Formulation AND pd<=20031104
   2 FILES SEARCHED...
L2 651 SORBITOL(S) FORMULATION AND PD<=20031104

=> Dup Rem L2
PROCESSING COMPLETED FOR L2
L3 565 DUP REM L2 (86 DUPLICATES REMOVED)
ANSWERS '1-37' FROM FILE MEDLINE
ANSWERS '38-58' FROM FILE BIOSIS
ANSWERS '59-561' FROM FILE CAPLUS
ANSWERS '562-565' FROM FILE EMBASE

=> S L5 AND G-CSF
L5 NOT FOUND
The L-number entered could not be found. To see the definition
of L-numbers, enter DISPLAY HISTORY at an arrow prompt (=>).

=> S L3 AND G-CSF
L4 0 L3 AND G-CSF

=> S L3 AND (granulocyte colony stimulating factor)
L5 1 L3 AND (GRANULOCYTE COLONY STIMULATING FACTOR)

=> D ibib abs l5

L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:641630 CAPLUS
DOCUMENT NUMBER: 143:139221
TITLE: Lipophilic-coated microparticle containing a protein drug and formulation comprising same
INVENTOR(S): Kim, Myung-jin; Kim, Sun-jin; Kwon, Kyu-chan; Kim, Joon
PATENT ASSIGNEE(S): S. Korea
SOURCE: U.S. Pat. Appl. Publ., 14 pp., Cont.-in-part of U.S. Ser. No. 160,784.
CODEN: USXXCO
DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005158392	A1	20050721	US 2004-24362	20041228
US 2003064105	A1	20030403	US 2002-160784	20020603 <--
PRIORITY APPLN. INFO.:			US 2002-160784	A2 20020603
			US 2000-648196	B2 20000825

AB A solid lipophilic microparticle having an average particle size ranging from 0.1 to 200 μm, comprising a lipophilic substance, hyaluronic acid or an inorg. salt thereof and an active ingredient selected from the group consisting of a protein or peptide drug, retains the full activity of the active ingredient, and when formulated in the form of an oil dispersion or oil-in-water emulsion, it releases in an in vivo environment the active ingredient in a controlled manner over a long period. Microparticles comprising hGH 2 mg/mL, Tween-80 0.01, sodium hyaluronate 0.2, and lecithin 1% and having average particle size 7 μm were prepared The microparticles were very stable and hGH was not denatured during the preparation of microparticles.

=> S L3 AND (3%-8%)
L6 5 L3 AND (3%-8%)

=> D Ibib ABS L6 1-5

L6 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:203795 CAPLUS
DOCUMENT NUMBER: 142:360818
TITLE: Antitumor erianin fat emulsion and its formulation
INVENTOR(S): Chen, Lizuan; Yang, Bingxun; Sun, Jijun
PATENT ASSIGNEE(S): Tianhuang Pharmaceutical Co., Ltd., Zhejiang, Peop. Rep. China
SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 15 pp.
CODEN: CNXXEV
DOCUMENT TYPE: Patent
LANGUAGE: Chinese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 1451378	A	20031029	CN 2003-117069	20030521 <--
PRIORITY APPLN. INFO.:			CN 2003-117069	20030521

AB The fat emulsion is composed of erianin 1.0-3.8, plant oil 100-250, emulsifying agent 6-15, osmotic pressure regulator 18-25 g, and water to 1,000 mL. The plant oil is soybean oil, corn oil, sesame oil, olive oil, etc. The emulsifying agent is soybean phospholipids or lecithin. The osmotic pressure regulator is glycerol, glucose, and/or sorbitol.

L6 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:59587 CAPLUS
DOCUMENT NUMBER: 140:92996
TITLE: Chewing gum formulation and production method
INVENTOR(S): Norman, Gary T.; Amin, Arun F.
PATENT ASSIGNEE(S): SPI Pharma, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 9 pp., Cont.-in-part of U.S. Ser. No. 245,419.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004013767	A1	20040122	US 2003-422502	20030424
US 7208186	B2	20070424		
US 2003086999	A1	20030508	US 2002-245419	20020917 <--
WO 2004032644	A2	20040422	WO 2003-US29074	20030916
WO 2004032644	A3	20050127		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003298583	A1	20040504	AU 2003-298583	20030916
EP 1538921	A2	20050615	EP 2003-796333	20030916
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				

PRIORITY APPLN. INFO.:

US 2001-323398P	P	20010918
US 2002-245419	A2	20020917
US 2003-422502	A	20030424
WO 2003-US29074	W	20030916

AB The chewing gum formulation is used to form a final chewing gum composition which contains an active ingredient which is released from the chewing gum as the gum is masticated in the mouth of the user. The chewing gum made from the chewing gum composition of the present invention is initially a compressed body, such as a tablet, which quickly dissocs. into a multiplicity of small pieces upon initial chewing followed by a reformation of the pieces into a coherent mass of chewing gum after a few seconds of chewing. Both the chewing gum formulation and the chewing gum composition are in the form of a free-flowing particulate which is capable of being directly compressed at high speed by a standard tableting machine into chewing gum tablets. Thus, the chewing gum formulation comprises 284.4 kg SorbogemTM 712, 3.8 kg Syloid 244FP and 72 kg Artica-T.

REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:874795 CAPLUS
DOCUMENT NUMBER: 139:354479
TITLE: Acidic aqueous chlorite teat dip composition with improved visual indicator stability and shelf life
INVENTOR(S): McSherry, David D.; Richter, Francis L.
PATENT ASSIGNEE(S): Ecolab Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 40 pp., Cont.-in-part of U.S. 6,436,444.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003206971	A1	20031106	US 2002-224300	20020819
US 6699510	B2	20040302		
US 6436444	B1	20020820	US 1997-938653	19970926 <--
EP 906724	A1	19990407	EP 1998-303896	19980518 <--
EP 906724	B1	20021009		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

AT 225606	T	20021015	AT 1998-303896	19980518 <--
ZA 9807953	A	20000322	ZA 1998-7953	19980901 <--
HK 1019036	A1	20030417	HK 1999-104118	19990922 <--

PRIORITY APPLN. INFO.: US 1997-938653 A2 19970926

AB The mastitis control teat dip composition having a visible indicator aspect of the invention provides a softening, soothing, smoothing, relaxing property, a rapid initial kill, a useful highly pseudoplastic rheol., a barrier/film-forming capacity, a unique antimicrobial composition that is stable over an extended period of time, and unexpected long term microbial control when compared to the prior art materials disclosed in patents and used in the marketplace. The indicator aspect provides ease of visually detecting the material on the animal skin and can indicate efficacy of the material. The compns. of the invention are made by combining an aqueous liquid composition containing the visual indicator combined with the organic components which can be combined with a simple aqueous solution of a salt of chlorous acid, preferably an alkali metal chlorite. The materials after they are combined and blended into a smooth viscous material containing an emollient package generates active antimicrobial chlorine dioxide and can be immediately contacted with the target animals. The compns. of the invention provide stable visual indication, rapid initial kill, consistent long term kill with chemical and rheol. stability. A 200-g batch of an exptl. base formulation contained 70% sorbitol 2.00, Neodol-259 1.00, pelargonic acid 1.00, lactic acid 5.90, water 158.98, octanesulfonate 14.00, 45% KOH 1.12, FD&C Green #3 8 .00, and pigment 8.00 g. The chlorite formulation contained water 500.00, and 25% sodium chlorite 500.00 g. About 200 g of the base formulation were mixed with 5.5 g the chlorite activator part. The pH of final mixture is about 2.9.

L6 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1988:443452 CAPLUS
DOCUMENT NUMBER: 109:43452
TITLE: Liquid temazepam formulation
INVENTOR(S): Way, Terry
PATENT ASSIGNEE(S): Farmitalia Carlo Erba Ltd., UK
SOURCE: Brit. UK Pat. Appl., 5 pp.
CODEN: BAXXDU
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 2185887	A	19870805	GB 1986-2664	19860204 <--
GB 2185887	B	19891206		
DE 3705074	A1	19880901	DE 1987-3705074	19870218 <--
CH 671881	A5	19891013	CH 1987-623	19870219 <--

PRIORITY APPLN. INFO.: GB 1986-2664 19860204

AB An oral composition of temazepam (I), which is only slightly soluble in water and is unstable in aqueous solution, contains ≤0.2% I, ≤15% of ≥1 polymeric alc., ≤45%of an aqueous solution of ≥1 hexahydric alc., ≥8% low-boiling alc., ≥40% weight/volume glycerol, a solubilizer, ≥1 flavoring agent, and buffers to maintain a pH of 7.3-8.3. A specific composition contained I 0.206, povidone 2.000, polyethylene glycol 400 5.000, absolute EtOH 8.800, glycerol 50.000, sodium phosphate 2.500, citric acid 0.125, chlorophyll 0.012, 70% sorbitol solution 45.000, peppermint oil 0.035, lemon flavor 0.060, glycerol to 100.000 g/100 mL. The product had 1.96-2.2 mg I/mL. On standing, the amount of I decreased to an acceptable 1.8 mg/mL, and remained within these limits for ≥21/2 years. Peak plasma levels

were attained .apprx.15 min after ingestion, compared to 30 min with capsules.

L6 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1970:22385 CAPLUS
DOCUMENT NUMBER: 72:22385
TITLE: Foamed resin articles
INVENTOR(S): Kitaj, Walter
PATENT ASSIGNEE(S): Owens-Illinois, Inc.
SOURCE: U.S., 8 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3477890	A	19691111	US 1968-699979	19680119 <--
PRIORITY APPLN. INFO.:			US 1968-699979 A	19680119

AB Rind-free foamed polyurethane structures of uniform d. were formed by applying a foamable polyurethane material as a liquid carrier between 2 porous fibrous sheets. Sufficient pressure was then applied to spread the liquid layer to a uniform thickness. After maintaining in liquid form without the addition of heat for a time sufficient to stabilize the layer, the autogenous foaming of the material was allowed to progress until the ultimate foamed thickness was achieved. The stabilization and autogenous foaming took 30-60 sec. Then, the outer surface of only 1 of the fibrous sheets was heated to 150-300°F to cure the foamed polyurethane. Higher edgewise compression strength was obtained than if both of the sheets were heated. Pressure was applied to the outer surface of the nonheated fibrous sheet while the foam was heated to smooth the fibrous sheet without compressing the polyurethane layer. A typical resin formulation consisted of Triol LK-380 33, diethylenetriaminepentapropanol (Pentol LA-700) 2, sorbitol -propylene oxide (Hexol G-2406) 3.8, silicon glycol copolymer (Silicone DC-113) 0.8, 1:2 triethylenediamine-1,2,6-hexanetriol 1.4, CCl3F 15.5, and crude diphenylmethane 4,4'-diisocyanate 43.5 parts. The laminates had improved strength through better uniformity of d. throughout their thickness. Porous cover films, such as paper, could be utilized with high bond strengths and high production.

=> D hist

(FILE 'HOME' ENTERED AT 19:12:24 ON 31 JUL 2007)

FILE 'MEDLINE, BIOSIS, CAPLUS, EMBASE' ENTERED AT 19:12:44 ON 31 JUL 2007
L1 0 S SORBITOL SAME FORMULATION AND PD<=20031104
L2 651 S SORBITOL(S)FORMULATION AND PD<=20031104
L3 565 DUP REM L2 (86 DUPLICATES REMOVED)
L4 0 S L3 AND G-CSF
L5 1 S L3 AND (GRANULOCYTE COLONY STIMULATING FACTOR)
L6 5 S L3 AND (3%-8%)

=> S l3 AND review
L7 6 L3 AND REVIEW

=> D Ti l7 1-6

L7 ANSWER 1 OF 6 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN
TI Final report on the safety assessment of PEG-20 Sorbitan Cocoate; PEG-40 Sorbitan Diisostearate; PEG-2, -5, and -20 Sorbitan Isostearate; PEG-40 and -75 Sorbitan Lanolate; PEG-10, -40, -44, -75, and -80 Sorbitan Laurate; PEG-3, and -6 Sorbitan Oleate; PEG-80 Sorbitan Palmitate; PEG-40

Sorbitan Perisostearate; PEG-40 Sorbitan Peroleate; PEG-3, -6, -40, and -60 Sorbitan Stearate; PEG-20, -30, -40, and -60 Sorbitan Tetraoleate; PEG-60 Sorbitan Tetrastearate; PEG-20 and -160 Sorbitantriisostearate; PEG-18 Sorbitan Trioleate; PEG-40 and -50 Sorbitol Hexaoleate; PEG-30 Sorbitol Tetraoleate Laurate; and PEG-60 Sorbitol Tetrastearate: Addendum to the final report on the safety assessment of Polysorbates.

L7 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN
TI The use of cyclodextrins for stabilization of Wasabia japonica ingredient and the development of new products

L7 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN
TI Applications of polyols in cosmetic formulations

L7 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN
TI Optimization of a formulation for oral pain relief

L7 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN
TI Polymeric polyisocyanates in urethane foams

L7 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN
TI Use of synthetic sweetening agents in pharmaceutical preparations and foods

=> D ibib abs 3, 4, 6

L7 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1987:604884 CAPLUS
DOCUMENT NUMBER: 107:204884
TITLE: Applications of polyols in cosmetic formulations
AUTHOR(S): Governor, R.
CORPORATE SOURCE: Hindustan Lever Res. Cent., Bombay, 400 099, India
SOURCE: Journal of the Oil Technologists' Association of India (Mumbai, India) (1986), 18(4), 133-6
CODEN: JOTIAC; ISSN: 0030-1485
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
AB A review with 9 refs. on the uses of polyols, (e.g., sorbitol, glycerol, propylene glycol) as humectants, emollients, etc. in cosmetic formulations.

L7 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1987:90094 CAPLUS
DOCUMENT NUMBER: 106:90094
TITLE: Optimization of a formulation for oral pain relief
AUTHOR(S): Fuertig, W.; Gaensicke, H.; Box, A.
CORPORATE SOURCE: Zent. Bereichs Med., Wilhelm-Pieck-Univ. Rostock, Rostock, Ger. Dem. Rep.
SOURCE: Pharmazeutische Praxis (1986), 41(5), 219-21
CODEN: PHPXAK; ISSN: 0048-3656
DOCUMENT TYPE: Journal
LANGUAGE: German
AB From a number of paracetamol [103-90-2]- and codeine phosphate [52-28-8]-containing oral formulations tested, the following formulation gave a stable mixture: paracetamol 12, EtOH [64-17-5] (90%) 50.0, Tinct. Aurantii 3.5, codeine phosphate 0.81, sodium saccharin 0.5, water 2.5 and sorbitol [50-70-4] (70%) to 190.0 g. In the absence of light the formulation was stable for 6 mo. Decreasing the EtOH content form 80.0 g to 50.0 g and increasing the sorbitol content improved the taste of the formulation. A review on the origin and possibilities of pain treatment and various analgesics used is given.

L7 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1965:416278 CAPLUS
DOCUMENT NUMBER: 63:16278
ORIGINAL REFERENCE NO.: 63:2847h,2848c
TITLE: Use of synthetic sweetening agents in pharmaceutical preparations and foods
AUTHOR(S): Brooks, L. G.
SOURCE: Chemist and Druggist (1965), 183(4445), 421-3
CODEN: CHDRA3; ISSN: 0009-3033
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The applications of sorbitol, saccharin, N-cyclohexylsulfamic acid are discussed with 13 formulations. 23 references.

=> Log Off H
SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 19:22:31 ON 31 JUL 2007